Loading...
Loading...
CCCC| Name | Value |
|---|---|
| Revenues | 15.4M |
| Cost of Revenue | 2.1M |
| Gross Profit | 13.3M |
| Operating Expense | 43.6M |
| Operating I/L | -28.2M |
| Other Income/Expense | 3.6M |
| Interest Income | 0.0M |
| Pretax | -24.7M |
| Income Tax Expense | -2.1M |
| Net Income/Loss | -24.7M |
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate, CFT7455, is an orally bioavailable MonoDAC degrader targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas. The company also develops other orally bioavailable degraders targeting various proteins for the treatment of solid tumors and cancers. C4 Therapeutics, Inc. generates revenue through strategic collaborations with pharmaceutical and biotechnology companies, focusing on advancing its pipeline of novel therapeutic candidates.
